Research Article

Antineuroinflammatory Effect of Amburana cearensis and Its Molecules Coumarin and Amburoside A by Inhibiting the MAPK Signaling Pathway in LPS-Activated BV-2 Microglial Cells

Ana Bruna de Araújo, Francisco Vinicius Clemente Serra Azul, Francisca Raysse Mesquita Silva, Talysson Silva de Almeida, João Victor Nunes Oliveira, Antônia Torres Ávila Pimenta, Antônio Marcos Esmeraldo Bezerra, Nuno J. Machado, and Luzia Kalyne Almeida Moreira Leal

1Centro de Estudos Farmacêuticos e Cosméticos (CEFAC), Departamento de Farmácia, Faculdade de Farmácia, Odontologia e Enfermagem, Universidade Federal do Ceará, Fortaleza, CE, Brazil
2Programa de Pós-Graduação em Ciências da Saúde, Universidade Federal do Ceará, Sobral, CE, Brazil

Correspondence should be addressed to Nuno J. Machado; nuno.machado.br@gmail.com and Luzia Kalyne Almeida Moreira Leal; kalyne@ufc.br

Received 10 February 2022; Accepted 21 March 2022; Published 28 April 2022

Academic Editor: Abdur Rauf

Copyright © 2022 Ana Bruna de Araújo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Microglia plays an important role in the neuroinflammatory response, identified as one of the major factors in the development and progression of neurodegenerative diseases. Amburana cearensis and its bioactive compounds, including coumarin (CM), vanillic acid (VA), and amburoside A (AMB), exert antioxidant, anti-inflammatory, and neuroprotective activities, on 6-OHDA-induced neurotoxicity in rat mesencephalic cells determined by our group. The present study investigated the anti-inflammatory effect of the dry extract from A. cearensis (DEAC), CM, AMB, and VA on lipopolysaccharide- (LPS-) stimulated microglial cells and elucidated the possible molecular mechanism of action. The DEAC was characterized by HPLC-PDA (chemical markers: CM, AMB, and VA). The BV-2 microglial cell line was pretreated with increasing concentrations of DEAC, CM, AMB, or VA in the presence or absence of LPS to evaluate the toxicity and anti-inflammatory activity. The cytotoxicity of DEAC, CM, AMB, or VA on BV-2 cells was evaluated by the MTT test, the free radical scavenging activity of test drugs was investigated, and the nitric oxide (NO) production was determined using the Griess reagent, while cytokine levels were measured by ELISA. The expressions of toll-like receptor 4 (TLR-4), nuclear factor kappa B (NF-κB), MAPK members (JNK and ERK1/2), and iNOS were determined through Western blot analysis. DEAC (100 μg/mL), as well as CM (50 and 100 μg/mL) and AMB (25 μg/mL), reduced at least 50% of NO produced and markedly decrease the production of TNF-α and IL-6 but they did not significantly affect IL-10 levels. Only DEAC (100 μg/mL) and AMB (25 μg/mL) reduced the expression of iNOS, and they did not affect arginase activity. DEAC (100 μg/mL) suppressed the activation of the MAPKs JNK and ERK1/2 in LPS-activated BV-2 cells but it did not suppress the expression of TLR-4 nor the phosphorylation of NF-κB. In conclusion, DEAC, CM, and AMB exerted anti-inflammatory activity in LPS-activated microglial cells as observed by the reduction in the production of inflammatory mediators and the expression of iNOS. We identified the MAPK signaling pathway as a probable mechanism of action to the anti-inflammatory effects observed.
1. Introduction

There is increasing evidence of the important role of neuroinflammation in the pathogenesis of several neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease [1–3]. The neuroinflammatory process includes a variety of events marked by the accumulation of various proinflammatory mediators, such as tumor necrosis factor alpha (TNF-α), interleukin 1β (IL-1β), interleukin 6 (IL-6), prostaglandins, nitric oxide (NO) (generated by inducible nitric oxide synthase (iNOS) and reactive oxygen species (ROS)). Microglia and astrocytes are the innate immune cells primarily involved in these proinflammatory mechanisms which cause damage to neuronal networks. In parallel, under physiological conditions, these cells have a protective function in preserving the homeostasis of the central nervous system (CNS) by secreting anti-inflammatory mediators and neurotrophic factors, such as transforming growth factor-β, interleukin 10 (IL-10), and arginase-1 [3, 4]. Thus, controlling microglial activation or modulating its phenotypes in response to damage-associated stimuli may be a promising strategy in the development of a therapy for neuroinflammatory diseases.

Microglial cells can be activated by various endogenous and environmental stimuli such as IFN-γ (interferon-gamma), glutamate, arachidonate, and lipopolysaccharide (LPS). LPS is found on the outer membrane of Gram-negative bacteria, acting as an endotoxin that binds to specific receptors, and it has been widely used to study inflammation due to its reproducible action and easy handling [5]. LPS induces activation of the toll-like receptor 4 (TLR-4) which activates nuclear factor kappa B (NF-kB) and mitogen-activated protein kinases (MAPKs) that play critical roles in the production of inflammatory mediators [6, 7].

Due to a deficit in therapeutic options, herbal products have been the focus of several studies for the treatment or prevention of neurodegenerative diseases [8, 9]. Amburana cearensis A. C. Smith (Fabaceae), a plant native to the Brazilian semi-arid region, has been extensively studied by our group that determined its chemical properties [10]. The neuroinflammatory and antioxidant activities of the extract of A. cearensis (wild or cultivated) and/or its chemical constituents, such as coumarin (CM), amburoside A (AMB), and vanillic acid (VA), have been the focus of several studies for the treatment or prevention of neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease [8, 9]. The neuroinflammatory and antioxidant activities of the extract of A. cearensis (wild or cultivated) and/or its chemical constituents, such as coumarin (CM), amburoside A (AMB), and vanillic acid (VA), have been the focus of several studies for the treatment or prevention of neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease [8, 9].

2. Materials and Methods

2.1. Preparation and Chemical Characterization of Dried Extract from Amburana cearensis Extract (DEAC).

To achieve a sustainable alternative for economic utilization of A. cearensis, in the last years, our research group became focused also on A. cearensis cultivated plant which has chemical and biological properties similar to the wild variety [16]. Seeds of A. cearensis were collected at the Quixeramobim region, Ceará State, Brazil, and voucher specimen (n° 52618) was deposited in the herbarium Prisco Bezerra, Department of Biology, Federal University of Ceará. A. cearensis seeds were cultivated, and seven months later, the plant was harvested from the garden beds, dried, and ground. The extraction was carried out by maceration for 24 h with ethanol as previously determined by our laboratory [17]. The drying process of the ethanol extract was performed at room temperature using a mini spray-dryer model LM MSD 1.0 (Labmaq do Brazil Ltda, Ribeirão Preto, SP, Brazil). The colloidal silicon dioxide was used as drying carrier (30% of the solid residues) with a feed flow of 1 L/h, inlet temperature of 100°C, and airflow of 40 L/min.

2.2. HPLC-PDA Analysis.

Dried extract of A. cearensis (DEAC) was analyzed by high-performance liquid chromatography–photodiode array (HPLC-PDA) (Waters) according to the method developed previously by our laboratory [10]. The analysis of the three chemical markers (coumarin (CM), amburoside A (AMB), and vanillic acid (VA)) was performed through their calibration curves, obtained by injection of external standards. The analysis of DEAC was performed in a C18 reverse phase column (4.6 mm × 250 mm) at a temperature of 45°C. The mobile phase was composed of acetonitrile (A), 0.01% phosphoric acid (B), and n-propanol (C), flow of 1 mL per minute. Detection was performed in a PDA detector using the wavelengths of 219 nm, 277 nm, and 220 nm for the determination of VA, CM, and AMB, respectively. The HPLC-PDA analysis of the DEAC allowed the identification and quantification of vanillic acid, amburoside, and coumarin.

2.3. Chemicals and Antibodies.

The amburoside A (AMB) was isolated from A. cearensis according to the methodology described previously by our group [18]. Vanillic acid (VA), coumarin (CM), N-(1-Naphthyl) ethylenediamine dihydrochloride (NEED), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), bovine serum albumin (BSA), 2-thiobarbituric acid (TBA), nitrotetrazolium blue chloride (NBT), hypoxanthine (HPX) and xanthine oxidase (XOD), phosphoric acid (H₃PO₄), ferric chloride (FeCl₃), hydrogen peroxide (H₂O₂), and L-ascorbic acid (vitamin C) were obtained commercially from Sigma-Aldrich, USA. Sulfanilamide and ethylenediaminetetraacetic acid tetrasodium salt dehydrate...
(EDTA) were purchased from Dinâmica Química Contepora-
ânea, Brazil. Trichloroacetic acid (TCA) was acquired from
Êxodo Científica, Brazil.

Fetal bovine serum (FBS) and cell culture medium
RPMI-1640 were purchased from Gibco, USA. Murine
microglial (BV-2) cells were acquired from Banco de Células
do Rio de Janeiro, Brazil.

The antibodies anti-NF-κB, p-NF-κB, JNK, p-JNK, and
p-ERK were obtained from Cell Signaling Technologies.
TLR-4 antibody was obtained from Invitrogen, Carlsbad,
CA, USA. Anti-iNOS, ERK, β-actin antibodies, and second-
ary antibodies (anti-rabbit and anti-mouse) were obtained
from Abcam Cambridge, UK. ELISA kits for TNF-α, IL-6,
IL-10, and IL-1β were purchased from BD Bioscience Phar-
mingen, San Diego, CA, USA.

2.4. Cell Culture Conditions. The murine BV-2 cells were
maintained in RPMI-1640 medium supplemented with
10% fetal bovine serum. The cells were grown to 70-80% confluency and incubated at 37°C in an atmosphere of 5%
CO₂.

2.5. Cell Viability Assay. Before conducting the anti-
flammatory activity test of the DEAC and its chemical
constituents, we performed the cytotoxicity test first in BV-
2 cells. The MTT test evaluated BV-2 cells’ viability using
the method previously described by Mosmann
[19]. The cells (1 × 10⁵ cells/mL) were plated in 96-well plates and treated with DEAC, CM, VA, or AMB (5, 10, 25, 50,
and 100 μg/mL) and 0.1% dimethyl sulfoxide (DMSO, Sigma-
Aldrich, USA) (drug vehicle) for 24 h. After the incubation
period, the salt 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) solution (0.5 mg/mL final
concentration) was added into the plate, then incubated for
90 minutes at 37°C. At last, the cells were centrifuged at
200 g for 10 minutes, the supernatant discarded, and the
formazan crystals dissolved in DMSO. The absorbance of
each well was recorded at 570 nm by using a plate reader
(Bio-Tek, Winooski, VT, USA).

2.6. NO Measurement. The concentration of nitrite in LPS-
induced BV-2 cells was determined by the Griess assay
[20]. The cells (1 × 10⁶ cells/mL) were plated in 96-well plates and treated with DEAC, CM, VA, or AMB (5, 10,
25, 50, and 100 μg/mL) and 0.1% DMSO (drug vehicle),
and 1 h later, LPS (0.5 μg/mL) was added. After 24 h, Griess
reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% N-(1-Naphthyl) ethylenediamine dihydrochloride (NEED) in
distilled water, 1 : 1) was added to cell medium at room
temperature, and 15 minutes later, absorbance at 540 nm
was measured using a spectrophotometer.

2.7. Measurement of Hydroxyl Radical. The hydroxyl radical was measured using the deoxyribose method according to
Zhao and colleagues [21] with modifications. Ascorbic acid
(1 mM), EDTA (1 mM), H₂O₂ (10 mM), FeCl₃ (1 mM), and
deoxyribose (DOR) (36 mM) were added to a reaction tube
with DEAC (100 μg/mL), CM (100 μg/mL), VA (100 μg/
ML), AMB (100 μg/mL), or 0.1% DMSO (drug vehicle) in
25 mM phosphate buffer (pH7.4) and incubated for 1 h at
37°C. TCA 10% and TBA 1% (prepared in NaOH 50 mM)
were added, and the solution was heated in a water bath at
85°C for 15 minutes. Absorbance at 532 nm was measured.

2.8. Assay for Superoxide Radical Scavenging Activity. Superoxide
generation was measured by a slight modification of the
previous method described by Hodgson and Fridovich
[22] using the hypoxanthine/xanthine oxidase (Sigma-
Aldrich, USA) system. Nitrotetrazolium blue chloride
(NBT), hypoxanthine (HPX), and xanthine oxidase (XOD)
solutions were prepared in Tris buffer. DEAC, CM, VA, or
AMB at 100 μg/mL, or 0.1% DMSO, were added to the reaction
solution containing 0.05 M Tris buffer, 5 × 10⁻³ M HPX,
and 10⁻³ M NBT. Then, 1.67 μg/mL XOD was added, except
in the negative control. The absorbance was measured at
560 nm every minute for 21 min.

2.9. Enzyme-Linked Immunosorbent Assay (ELISA). BV-2 cells were pretreated with DEAC (100 μg/mL), AMB
(25 μg/mL), CM (50 and 100 μg/mL), or 0.1% DMSO (drug vehicle) for 1 h, then stimulated with LPS (0.5 μg/mL) for
24 h. The levels of TNF-α, IL-6, IL-1β, and IL-10 in the cul-
supernatant were quantified using commercially avail-
able ELISA kits (BD Bioscience Pharmingen, San Diego,
CA, USA) according to the manufacturer’s protocol.

The absorbance at 450 nm was measured using a microplate
reader.

2.10. Western Blot Analysis. BV-2 microglial cells (1 × 10⁶
cells/mL) were pretreated with DEAC (100 μg/mL), CM (50,
100 μg/mL), AMB (25 μg/mL), or 0.1% DMSO (drug vehicle)
for 1 h. The cells were incubated for 1 h or 24 h. The cells were harvested, and adherent cells were resuspended in
ice-cold phosphate-buffered saline (PBS). Cellular proteins were extracted by incubating with
radioimmunoprecipitation assay buffer (RIPA) containing
protease inhibitor cocktail (1 : 20), phenylmethylsulfonyl fluo-
ride (1 : 50), and phosphatase inhibitor cocktail set III (1 : 20).

The cell lysate was centrifuged at 12500 × g for 10 min at
4°C, and the supernatant was kept as the protein extract.

Protein concentration was determined with a BCA kit using
Laemmli bufer. Equal amounts of protein (30 μg) from each sample were subjected to 7.5-10% SDS-PAGE and transferred to
PVDF membranes. After blocking at room temperature with
5% nonfat dry milk or 5% BSA for 1 h, the blocked membranes
were incubated for 18 h with primary antibodies against p-NF-
κB 1 : 1000 (#3033S), NF-κB 1 : 2000 (#6965S), p-ERK1/2
1 : 1000 (#9101S), ERK1/2 1 : 1000 (ab36991), p-JNK 1 : 1000
(#9255S), JNK 1 : 2000 (#9252S), iNOS 1 : 1000 (ab178945),
TLR-4 1 : 200 (482300), and β-actin 1 : 5000 (ab8226) at 4°C.

After washing three times with TBS-T (10 mM Tris-HCl
(pH7.4), 150 mM NaCl, 0.1% Tween 20), the membranes
were incubated with the secondary antibody for 2 h at room
temperature. Protein bands were visualized using enhanced
chemiluminescence reagent (Bio-Rad, USA) in an imaging

Oxidative Medicine and Cellular Longevity
system (Chemidoc MP, Bio-Rad, USA) [23], and the protein levels were analyzed using the ImageLab 6 software (Bio-Rad, USA) and normalized with β-actin or total proteins.

2.11. Analysis of Arginase Activity. Arginase activity was evaluated according to the method described by Corraliza et al. [24]. BV-2 cells (1 × 10⁶ cells/mL) were pretreated with DEAC or CM (100 μg/mL) or 0.1% DMSO (drug vehicle), for 1 h before the addition of LPS (0.5 μg/mL), or vehicle. After 24 h, cells were lysed with buffer containing 0.1% Triton X-100. The enzyme was activated by heating the plates for 10 minutes at 55°C, using enzyme activation buffer (10 mM MnCl₂, 25 mM Tris-HCl). The hydrolysis of L-arginine (25 μL, 0.5 M, pH 9.7) was induced through the incubation of lysate (50 μL) with 25 μL of L-arginine (Sigma-Aldrich, USA) 0.5 M (pH 9.7) during 60 min at 37°C. The reaction was stopped with 400 μL of buffer containing H₂SO₄/H₃PO₄/H₂O (1/3/7, v/v/v). After the addition of α-isonitrosopropiophenone (25 μL, 9%) and heating for 30 minutes at 95°C, the concentration of urea (final product of the reaction) was determined by spectrophotometric analysis (540 nm). The concentrations of urea were interpolated from the linear equation obtained from the standard curve generated by known concentrations of urea (1.5 to 300 μg/mL).

2.12. Statistical Analysis. Statistical analyses were performed using the GraphPad Prism 6.01 software (GraphPad Software, Inc.), and all results were expressed in ± SEM (standard error of mean). Differences were evaluated by one-way ANOVA or two-way ANOVA with Bonferroni’s post hoc test or one-sample t-test. Statistical significance was considered when p < 0.05.

3. Results

3.1. Standardized DEAC and Its Active Compounds Are Not Toxic to BV-2 Microglial Cells. The dried extract of A. cearensis (DEAC) was characterized by HPLC-PDA as shown in Figure 1(a). The HPLC analysis allowed to detect and quantify three compounds (mg/g of dried extract): vanillic acid (2.70 ± 0.01 mg/g), amburoside A (30.40 ± 0.01 mg/g), and coumarin (70.07 ± 0.01 mg/g). To first evaluate the effect of DEAC and its chemical constituents on cell viability by MTT test, we pretreated BV-2 microglial cells with increasing concentrations of test drugs. As shown in Figure 1(b), the treatment of cells with DEAC, CM, AMB, or VA (5, 10, 25, 50, and 100 μg/mL) did not significantly affect the viability of cells when compared to the control group (100% of viability) (see Figure 1).

3.2. DEAC, CM, and AMB Reduce NO Production in LPS-Stimulated Microglial Cells. Microglia plays a central role in neuroinflammation being responsible for the synthesis and release of a wide array of chemical mediators including cytokines such as TNF-α, IL-1β, IL-6, ROS, and NO. First, we investigated the effect of DEAC and its active principles (AMB, CM, and VA) on nitrte production of LPS-stimulated microglial cells. The addition of DEAC or its chemical constituents in increasing concentrations did not alter the basal levels of NO in BV-2 cells (data not shown). LPS increased NO release by approximately 13x (Figure 2) in microglial cells when compared to the untreated group (control group). This effect was significantly reduced by the pretreatment of cells with noncytotoxic concentrations of DEAC, AMB, or CM, reaching maximal reduction at 100 μg/mL (nitrite: 6.1 ± 1.0 μM, 4.4 ± 1.4 μM, and 7.0 ± 1.5 μM, respectively). The LPS-only groups released nitrite at the following concentrations: 13.0 ± 1.4 μM, 16.7 ± 0.2 μM, and 23.6 ± 2.8 μM, respectively. AMB in particular showed a significant reduction in the NO production from 25 μg/mL. The pretreatment of the BV-2 cells with VA did not significantly interfere in the NO production induced by LPS.

3.3. DEAC, CM, and AMB Regulate Cytokine Production in LPS-Stimulated Microglial Cells. Considering the results obtained in the Griess assay, we chose the lowest anti-inflammatory concentration for each drug (DEAC, AMB, and CM) to evaluate their effects on the production of proinflammatory and anti-inflammatory cytokines (Figures 3(a)–3(i)). The addition of LPS for 24 h induced a significant increase in the TNF-α, IL-6, and IL-1β levels while IL-10 levels (anti-inflammatory cytokine) were reduced when compared to the untreated group. Pretreatment of cells with DEAC, AMB, or CM for 1 h before the addition of LPS significantly reduced the concentration of proinflammatory cytokines. On the other hand, the reduction of IL-10 induced by LPS on BV-2 cells was not significantly affected by the tested drugs, although DEAC and AMB increased its concentration by approximately 20.6% and 62.7%, respectively, compared to the LPS group.

3.4. DEAC, CM, and AMB Slow Free Radical Scavenging Activity: Hydroxyl Radical and Superoxide Anion. An excessive amount of ROS produced by activated microglial cells can lead to cell damage and apoptosis. We investigated the possible oxygen free radical scavenging activity of DEAC and its active principles. DEAC, CM, VA, and AMB showed effective anion superoxide and hydroxyl radical scavenging activity (Figure 4). Superoxide anion scavenging activity of AMB (100 μg/mL) was found to be 77.0 ± 12.3%, an effect comparable to gallic acid used as a reference compound (81.4 ± 7.1%). DEAC, CM, and VA exhibited scavenging activity of 55.2 ± 10.8%, 33.3 ± 3.3%, and 43.0 ± 4.0%, respectively. The scavenging effect of DEAC and its active principles on the hydroxyl radical decreased in the order of DEAC > VA > AMB > CM.

3.5. Effect of DEAC, AMB, and CM in LPS-Induced iNOS Expression in BV-2 Cells by Western Blot. Following the study, we investigated whether the suppression of NO production by DEAC, AMB, or CM was related to the expression of its synthase, iNOS. LPS induced a significant increase in the density of iNOS, but this effect was significantly reduced by the pretreatment with DEAC (100 μg/mL) or AMB (25 μg/mL) (Figure 5). On the other hand, the treatment of BV-2 cells with CM did not affect iNOS.
Figure 1: Chromatographic profile of dry extract from *A. coarensis* (DEAC) and identification of three compounds (a). Effect of DEAC (i), CM (ii), AMB (iii), and VA (iv) (5-100 μg/mL) in BV-2 cell viability measured through the MTT assay. Data are shown as percentage of controls (CTR; 0.1% DMSO). Results are expressed as the mean ± SEM. ANOVA test followed by the Bonferroni posttest, n = 4/group.
expression. In the absence of LPS, DEAC and its active principles did not change the expression of iNOS.

3.6. DEAC and CM Did Not Prevent the Reduction of Arginase Activity Induced by LPS in BV-2 Cells. The addition of LPS (0.5 μg/mL) to BV-2 cells significantly reduced arginase activity, measured by the concentration of urea (50.5 ± 7.7 μg/mL) when compared to the nontreated group (87.2 ± 11.6 μg/mL). In the absence of LPS, only CM (100 μg/mL: 10.3 ± 0.6 μg/mL), but not DEAC (100 μg/mL: 93.0 ± 12.0 μg/mL), significantly reduced the concentration of urea. None of DEAC or CM was able to prevent the reduction of arginase activity when compared to the LPS group (LPS 0.5 μg/mL). A tendency to increase arginase activity by approximately 15.4%.

3.7. Effects of DEAC in LPS-Induced TLR-4/NF-κB/ERK1/2 and JNK Pathways. LPS induces an inflammatory response by interacting with the TLR-4 receptor. We first investigated the effect of DEAC on the expression of this receptor in BV-2 cells, followed by the analysis of the phosphorylation of its downstream signaling proteins (NF-κB and MAPKs). Western blotting results showed that the LPS exposure significantly increased the expression of TLR-4 in BV-2 cells when compared to the control group (not the treated group). However, DEAC pretreatment did not significantly prevent this increase (Figure 6(a)). As shown in Figures 6(b) and 6(c), LPS stimulation resulted in the phosphorylation of ERK1/2 and JNK, and DEAC pretreatment significantly decreased the phosphorylation of both MAPKs. Phosphorylation of NF-κB was not changed by DEAC (Figure 6(d)).

4. Discussion
Evidence suggests that exacerbated neuroinflammation response in the central nervous system is decisively related to degenerative processes in several neurological diseases, including multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. Moreover, the literature has shown that microglial activation has a key role in the progression of those diseases [25–27]. Therefore, regulating neuroinflammation is a therapeutic goal. The present work sought to investigate the effects of standardized dried extract of A. cearensis (DEAC) and its chemical constituents (CM, AMB, and VA) in LPS-induced inflammation in microglial

![Figure 2: Effect of DEAC (a), CM (b), AMB (c), and VA (d) (5-100 μg/mL) in LPS-induced nitrite production. BV-2 cells were pretreated with the drugs for 1 h and incubated with or without LPS (0.5 μg/mL) for 24 h. All values are expressed as mean ± SEM of concentration of nitrite. One-way ANOVA was used followed by the Bonferroni posttest. #vs. control group (DMSO 0.1%) (p < 0.05), *p < 0.05; **p < 0.01 vs. LPS group, n = 4/group.](image)
Figure 3: Continued.
cells. When activated, these cells release several inflammatory and potentially neurotoxic mediators, including proteases, excitatory amino acids, cytokines, ROS, and reactive nitrogen species (RNS). Lipopolysaccharide, a bacterial endotoxin, is extensively used as an inflammatory stimulus for microglial activation [28]. This experimental model has been a useful tool to understand the role of neuroinflammation in the progression of neurological diseases. The production of inflammatory mediators after stimulation with LPS is the result of a sequence of reactions that begins at the binding of LPS to cell membrane receptors which activate a cascade of intracellular signaling pathways, resulting in the release of several mediators, including nitric oxide (NO).

DEAC and its compounds, except VA, decreased nitrite production, elevated by the exposure to LPS, without significantly affecting cell viability, as assessed by the MTT test. Additionally, the plant extract and all chemical constituents evaluated (CM, AMB, and VA) showed antioxidant activity, acting as scavengers of hydroxyl and superoxide anion radicals. These results are consistent with previous studies developed by our laboratory which showed the anti-inflammatory and antioxidant effect of AMB and isokaempferide (flavonol) from A. cearensis in mesencephalic cells of rats exposed to the neurotoxin 6-hydroxydopamine (6-OHDA), human neutrophils, and/or CCl4-induced hepatotoxicity in rats [11, 18, 29].

Nitric oxide is associated with both beneficial and deleterious effects in humans. In the central nervous system (CNS), the iNOS upregulation and the accumulation of NO exacerbate the neuroinflammatory microenvironment, which contributes to neuronal cell death. The toxicity of NO is enhanced when it is combined with superoxide anion, generating peroxynitrite anion [30]. Decomposition of peroxynitrite results in the formation of some highly reactive species such as hydroxyl radicals [31]. Previous studies [32, 33] showed that higher hydroxyl radical levels and lower superoxide dismutase activity, an oxidoreductase responsible to dismutate the superoxide anion, seem to contribute to the onset and progression of neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s disease. Therefore, the
reduction of nitrite concentration and the scavenging activity of hydroxyl and superoxide anion radicals exerted by DEAC and its active compounds suggest that DEAC’s anti-inflammatory effects reduce the accumulation of reactive oxygen and nitrogen species (ROS/RNS) which play a major role in neuroinflammation-induced neuronal death [34].

Corroborating these data, Yeo et al. [35], describing the anti-inflammatory activity of a Piper sarmentosum extract in microglial cells, showed that the inhibition of NO production by the plant extract was associated with its free radical scavenging property.

Apart from NO, proinflammatory cytokines such as IL-1β, IL-6, and TNF-α are triggers of the inflammatory response and contribute to maintaining the high microglial activity that sustains the development of chronic inflammatory diseases [25]. These pathologies can be controlled by reducing the proinflammatory response and/or improving natural anti-inflammatory mechanisms. Thus, our study also investigated the effect of DEAC, CM, or AMB on the level of inflammatory and anti-inflammatory cytokines in LPS-stimulated BV-2 cells. Importantly, DEAC, CM, and AMB inhibited LPS-induced release of proinflammatory cytokines (TNF-α and IL-6), but we did not observe significant effects on the IL-10 (anti-inflammatory cytokine) reduction caused by LPS. Collectively, these data suggest that DEAC and its active principles CM and AMB may protect against neuronal death considering that IL-1β and TNF-α act synergistically as neurotoxic agents mediated at least in part by NO [36]. This hypothesis is corroborated by previous studies [15] where we described the anti-inflammatory and antioxidant activities of AMB from A. cearensis in mesencephalic cells of rats exposed to neurotoxin 6-OHDA.

NO synthesis can be limited by arginine availability and/or on the level of iNOS protein expression. During the NO synthesis, arginase-1 (expressed in microglial cells) competes with iNOS for L-arginine [37, 38]. Therefore, we investigated the effect of DEAC and its compounds on iNOS expression and arginase catalytic activity in LPS-stimulated BV-2 cells. We observed that LPS induced an increase in iNOS expression in BV-2 microglial cells, and pretreatment with DEAC or AMB decreased the expression of this enzyme. Meanwhile, the addition of CM in BV-2 cells did not affect the iNOS expression, and none of the test drugs improved the arginase activity when compared to the LPS-only group. Taken together, these results demonstrate that the inhibition of NO production by the extract of A. cearensis and AMB in microglial cells is related, at least in part, to their ability to reduce iNOS expression in microglial cells. Additional

Figure 5: Effects of DEAC (a), CM (b), and AMB (c) on iNOS expression in LPS-stimulated BV-2 cells. Cells were pretreated with DEAC (100 μg/mL), CM (50 and 100 μg/mL), or AMB (25 μg/mL) for 1 h and incubated with LPS (0.5 μg/mL) for additional 24 h. Two-way ANOVA in graphs (a) and (c), and one-way ANOVA for graph (b), followed by Bonferroni posttest. *p < 0.05 vs. negative control (0.1% DMSO, drug vehicle), **p < 0.01; ***p < 0.001 vs. LPS group, n = 4/group.
studies are necessary to describe how CM reduced the nitrite production in LPS-stimulated BV-2 cells without affecting iNOS expression. We hypothesize that it may act as an iNOS inhibitor.

The anti-inflammatory and antioxidant activities of DEAC described in the present study in microglial cells are corroborated by a previous study by Pereira et al. [13] which described the neuroprotective effect of an A. cearensis seed extract against neural damage induced by glutamate in cerebellar cells, which was associated to glial and neuronal preservation, and antioxidant activity. As DEAC’s main bioactive markers CM and AMB showed a promising anti-inflammatory effect, we then further described the mechanisms underlying DEAC-mediated attenuation of inflammation in BV-2 cells. There are several published works describing A. cearensis or its active principles’ anti-inflammatory or antioxidant activities [10, 11, 15, 17, 29, 39–41]. However, these studies are mainly confined to just showing their effects without further investigating the molecular mechanism underlying them. Therefore, the present study investigated the role of TLR-4, NF-κB, and MAPK signaling pathways in the anti-inflammatory effect of DEAC in LPS-stimulated BV-2 cells. The binding of TLR-4 on the cell membrane by LPS in BV-2 cells activates various signaling cascades, including NF-κB pathway via the MyD88–IRAK–TRAF6–TAK1 signaling complex leading to the activation of IκB kinase complex (IKK). Activation of IKK includes the phosphorylation of NF-κB which leads to its translocation to the nucleus. As a transcription factor, NF-κB stimulates the synthesis of proinflammatory mediators including NO, IL-6, and TNF-α and the secretion of ROS. In addition to NF-κB, LPS is a potent activator of the MAPK signaling pathways, which in turn modulate the activation of several transcription factors, including activator protein-1 (AP-1), STAT-1, and NF-κB. AP-1 upregulates cytokine expression playing a key role in neuroinflammation [42–45]. In the present study, we found that DEAC treatment significantly inhibited LPS-stimulated phosphorylation of two MAP kinase pathways (JNK and ERK1/2) in microglial cells. However, DEAC did not interfere in the increased expression of TLR-4 or phosphorylation of NF-κB induced by LPS (Figure 7).

Evidence demonstrates that excessive production of inflammatory mediators acts as inducers of MAPKs which in turn amplify and prolongs the inflammation process [45]. This vicious cycle leads to neuronal damage and death.
which is a hallmark of neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) [45]. Both JNK and ERK promote the phosphorylation of amyloid precursor protein that, when cleaved by β- and γ-secretases, yields the neurotoxic β-amyloid peptide which plays a key role in AD. In addition, studies demonstrated that TNF-α, a classical factor secreted from activated microglia, can induce a significant increase in the α-SNC secretion (a marker of PD) from both differentiated PC12 and SHSY5Y cells [35, 42]. Therefore, the inhibition of MAPK pathways by DEAC indicates that it may be a promising anti-inflammatory drug, useful for the treatment of neurodegenerative disorders.

The anti-inflammatory effect of DEAC is associated at least in part with the presence of AMB and CM in the plant extract, but the pharmacological importance of other chemical constituents from A. cearensis cannot be excluded. Moreover, the present work studied the effects of different drugs in an isolated microglial cell line; therefore, the anti-inflammatory activity observed may not fully represent an in vivo effect in reducing neuroinflammation. Because of this, future trials should be carried out using experimental animal models of neurodegenerative diseases to evaluate the effect of DEAC, AMB, and CM, investigating the anti-inflammatory, antioxidant, and consequent neuroprotective potential. The in vivo study will allow to know if these drugs have limitations associated to bioavailability and how they act in living system with complex interplay between the different cell types at different time points in the progression of neuroinflammatory diseases.

5. Conclusion

Taken together, our results demonstrate that DEAC and its active principles (AMB and CM) (100 μg/mL) have free radical scavenging activity and inhibit the production of NO (up to 100 μg/mL). At their concentrations that reduced at least 50% of NO production, they also reduced the release of the proinflammatory cytokines TNF-α and IL-6 as well as the expression of iNOS in LPS-stimulated BV-2 microglial cells (DEAC at 100 μg/mL, CM at 50 and 100 μg/mL, and AMB at 25 μg/mL). These effects were not related to cytotoxicity and seem to occur through inhibition JNK and ERK1/2 MAPK pathways (DEAC at 100 μg/mL). These data provide an experimental basis that the standardized dry extract of A. cearensis (cultivated species), CM, and AMB presents therapeutic potential for the treatment of inflammatory diseases where microglial activation plays a key role, such as neurodegenerative diseases.
Abbreviations

6-OHDA: 6-Hydroxydopamine
AD: Alzheimer’s disease
AMB: Amburoside A
AP-1: Activator protein-1
BSA: Bovine serum albumin
CNS: Central nervous system
CM: Coumarin
DEAC: Dry extract from Amburana cearensis
DMSO: Dimethyl sulfoxide
EDTA: Ethylenediaminetetraacetic acid tetrasodium salt dihydrate
ERK: Extracellular signal-regulated kinase
FBS: Fetal bovine serum
FeCl3: Ferric chloride
H2O2: Hydrogen peroxide
H3PO4: Phosphoric acid
HPLC-PDA: High-performance liquid chromatography–photodiode array
HPX: Hypoxanthine
IFN-γ: Interferon-gamma
IKK: IκB kinase complex
IL: Interleukin
iNOS: Inducible nitric oxide synthase
JNK: C-Jun N-terminal kinase
κB: Nuclear factor kappa B
L-Ascorbic acid: Vitamin C
LPS: Lipopolysaccharide
MAPKs: Mitogen-activated protein kinases
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NBT: Nitrotetrazolium blue chloride
NEED: N-(1-Naphthyl)ethylenediamine dihydrochloride
NF-κB: Nuclear factor kappa B
NO: Nitric oxide
PBS: Phosphate-buffered saline
PD: Parkinson’s disease
RIPA: Radioimmunoprecipitation assay buffer
RN5: Reactive nitrogen species
ROS: Reactive oxygen species
SDS: Sodium dodecyl sulfate
TBA: 2-Thiobarbituric acid
TCA: Trichloroacetic acid
TLR-4: Toll-like receptor 4
TNF-α: Tumor necrosis factor alpha
VA: Vanillic acid
XOD: Xanthine oxidase.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Acknowledgments

L.K.A.M. Leal acknowledges the Brazilian National Research Council (CNPq) for their research fellowships (316948/2021-7). This work was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES), the Research Foundation of the State of Ceara (FUNCAP), and CNPq.

References

[1] F. Leng and P. Edison, “Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?,” *Nature Reviews Neurology*, vol. 17, no. 3, pp. 157–172, 2021.
[2] R. M. Ransohoff, “How neuroinflammation contributes to neurodegeneration,” *Science*, vol. 353, no. 6301, pp. 777–783, 2016.
[3] Z. Yu, L. Tang, L. Chen, J. Li, W. Wu, and C. Hu, “Capillarisin suppresses lipopolysaccharide-induced inflammatory mediators in BV2 microglial cells by suppressing TLR4-mediated NF-κB and MAPKs signaling pathway,” *Neurochemical Research*, vol. 40, no. 6, pp. 1095–1101, 2015.
[4] S.-C. Ho, K.-S. Chang, and P.-W. Chang, “Inhibition of neuroinflammation by cinnamon and its main components,” *Food Chemistry*, vol. 138, no. 4, pp. 2275–2282, 2013.
[5] L. Heinbockel, G. Weindl, G. Martinez-de-Tejada et al., “Inhibition of lipopolysaccharide- and lipoprotein-induced inflammation by antitoxin peptide Pep19-2.5,” *Frontiers in Immunology*, vol. 9, pp. 1–6, 2018.
[6] W. Abate, A. A. Alghaithy, J. Parton, K. P. Jones, and S. K. Jackson, “Surfactant lipids regulate LPS-induced interleukin-8 production in A549 lung epithelial cells by inhibiting translocation of TLR4 into lipid raft domains,” *Journal of Lipid Research*, vol. 51, no. 2, pp. 334–344, 2010.
[7] X. Zhu, J. S. Owen, M. D. Wilson et al., “Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol[S],” *Journal of Lipid Research*, vol. 51, no. 11, pp. 3196–3206, 2010.
[8] H. G. Kim, G. Park, Y. Piao et al., “Effects of the root bark of Paeonia suffruticosa on mitochondria-mediated neuroprotection in an MPTP-induced model of Parkinson’s disease,” *Food and Chemical Toxicology*, vol. 65, pp. 293–300, 2014.
[9] N. S. Mohd Sairazi and K. N. S. Sirajudeen, “Natural products and their bioactive compounds: neuroprotective potentials against neurodegenerative diseases,” *Evidence-based Complementary and Alternative Medicine*, vol. 2020, 7 pages, 2020.
[10] H. H. D. S. Amaral, “Extrauto seco padronizado de Amburana cearensis cultivada e constituintes quimicos modulam a inflamação em um novo modelo de asma exacerbada em camundongos BALB/C e a resposta neutrofílica em vitro,” *Universidade Federal do Ceará*, 2017.
[11] L. K. A. M. Leal, K. M. Canuto, K. C. da Silva Costa et al., “Effects of amburoside a and isokaempferide, polyphenols from amburana cearensis, on rodent inflammatory processes and myeloperoxidase activity in human neutrophils,” *Basic and Clinical Pharmacology and Toxicology*, vol. 104, no. 3, pp. 198–205, 2009.
[12] J. H. C. E. Silva, R. S. Ferreira, E. P. Pereira et al., “Amburana cearensis: pharmacological and neuroprotective effects of its compounds,” *Molecules*, vol. 25, no. 15, pp. 3316–3394, 2020.
[13] É. P. Lima Pereira, C. Santos Souza, J. Amparo et al., “Amburana cearensis seed extract protects brain mitochondria from oxidative stress and cerebellar cells from excitotoxicity induced by glutamate,” *Journal of Ethnopharmacology*, vol. 209, pp. 157–166, 2017.

[14] E. C. Pereira, D. L. Lucetti, J. M. Barbosa-Filho et al., “Coumarin effects on amino acid levels in mice prefrontal cortex and hippocampus,” *Neuroscience Letters*, vol. 454, no. 2, pp. 139–142, 2009.

[15] L. K. A. M. Leal, H. V. N. Júnior, G. M. A. Cunha et al., “Amburasis A. glucoside from Amburana cearensis, protects mesencephalic cells against 6-hydroxydopamine-induced neurotoxicity,” *Neuroscience Letters*, vol. 388, no. 2, pp. 86–90, 2005.

[16] L. K. A. M. Leal, T. M. Pierdoná, J. G. S. Góes et al., “A comparative chemical and pharmacological study of standardized extracts and vanillic acid from wild and cultivated Amburana cearensis A.C. Smith,” *Phytochemistry*, vol. 18, no. 2-3, pp. 230–233, 2011.

[17] N. R. Lima, “Desenvolvimento farmacêutico e avaliação farmacológica do extrato padronizado (CLAE-DAD) e constituíntes químicos de Amburana cearensis (cumaru) cultivado,” *Universidade Federal do Ceará*, 2013.

[18] K. M. Canuto, E. R. Silvera, and A. M. E. Bezerra, “Estudo fitoquímico de espécimens cultivados de cumaru (Amburana cearensis A. C. Smith),” *Química Nova*, vol. 33, no. 3, pp. 662–666, 2010.

[19] T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” *Journal of Immunological Methods*, vol. 65, no. 1-2, pp. 55–63, 1983.

[20] L. C. Green, D. A. Wagner, J. Głogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum, "Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids," *Analytical Biochemistry*, vol. 126, no. 1, pp. 131–138, 1982.

[21] H. Zhao, J. Dong, J. Lu et al., "Effects of extraction solvent mixtures on antioxidant activity evaluation and their extraction capacity and selectivity for free phenolic compounds in barley (Hordeum vulgare L.)," *Journal of Agricultural and Food Chemistry*, vol. 54, no. 19, pp. 7277–7286, 2006.

[22] E. K. Hodgson and I. Fridovich, "The accumulation of superoxide radical during the aerobic action of xanthine oxidase A requiem for H₂O₄," *Biochimica et Biophysica Acta*, vol. 430, no. 1, pp. 182–188, 1976.

[23] Z. Zhao, L. Tao, A. Liu et al., "NF-κB is a key modulator in the signaling pathway of Borrelia burgdorferi BmpA-induced inflammatory chemokines in murine microglia BV2 cells," *Molecular Medicine Reports*, vol. 17, no. 4, pp. 4953–4958, 2018.

[24] I. M. Corraliza, M. L. Campo, G. Soler, and M. Modolell, "Determination of arginase activity in macrophages: a micromethod," *Journal of Immunological Methods*, vol. 174, no. 1–2, pp. 231–235, 1994.

[25] S. Bachiller, I. Jiménez-Ferrer, A. Paulus et al., "Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response," *Frontiers in Cellular Neuroscience*, vol. 12, pp. 1–17, 2018.

[26] H. S. Kwon and S.-H. Koh, "Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes," *Translational Neurodegeneration*, vol. 9, no. 1, p. 42, 2020.

[27] L. Muzio, A. Viotti, and G. Martino, "Microglia in neuroinflammation and neurodegeneration: from understanding to therapy," *Frontiers in Neuroscience*, vol. 15, 2021.

[28] S. Lively and L. C. Schlichter, "Microglia responses to pro-inflammatory stimuli (LPS, IFNγ+TNFα) and reprogramming by resolving cytokines (IL-4, IL-10)," *Frontiers in Cellular Neuroscience*, vol. 12, p. 215, 2018.

[29] L. K. A. M. Leal, F. Fonseca, F. Pereira et al., "Protective effects of amburoside A, a phenol glucoside from Amburana cearensis, against CCl₄-induced hepatoxicity in rats," *Planta Medica*, vol. 74, no. 5, pp. 497–502, 2008.

[30] H. L. Hsieh and C. M. Yang, "Role of redox signaling in neuroinflammation and neurodegenerative diseases," *Bio Med Research International*, vol. 2013, 2013.

[31] S. Tharmalingam, A. Alhasawi, V. P. Appanna, J. Lemire, and V. D. Appanna, "Reactive nitrogen species (RNS)-resistant microbes: adaptation and medical implications," *Biological Chemistry*, vol. 398, no. 11, pp. 1193–1208, 2017.

[32] E. Kienzl, K. Jellinger, H. Stachelberger, and W. Linert, "Iron as catalyst for oxidative stress in the pathogenesis of Parkinson’s disease?", *Life Sciences*, vol. 65, no. 18–19, pp. 1973–1976, 1999.

[33] F. Collin, "Chemical basis of reactive oxygen species reactivity and involvement in neurodegenerative diseases," *International Journal of Molecular Sciences*, vol. 20, no. 10, 2019.

[34] J. E. Yuste, E. Tarragon, C. M. Campuzano, and F. Ros-Bernal, "Implications of glial nitric oxide in neurodegenerative diseases," *Frontiers in Cellular Neuroscience*, vol. 9, pp. 1–13, 2015.

[35] E. T. Y. Yeo, K. W. L. Wong, M. L. See, K. Y. Wong, S. Y. Gan, and E. W. L. Chan, "Piper sarmentosum Roxb. confers neuro-protection on beta-amyloid (Aβ)-induced microglia-mediated neuroinflammation and attenuates tau hyperphosphorylation in SH-SY5Y cells," *Journal of Ethnopharmacology*, vol. 217, pp. 187–194, 2018.

[36] C. C. Chao, S. X. Hu, L. Ehrlich, and P. K. Peterson, "Interleukin-1 and tumor necrosis factor-a synergistically mediate neurotoxicity: involvement of nitric oxide and of n-methyl-d-aspartate receptors," *Brain Behavior and Immunity*, vol. 9, no. 4, pp. 355–365, 1995.

[37] M. Rath, I. Müller, P. Kropf, E. I. Closs, and M. Munder, "Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages," *Frontiers in Immunology*, vol. 5, pp. 1–11, 2014.

[38] C. D. Mills, L. L. Lenz, and K. Ley, "Macrophages at the fork in the road to health or disease," *Frontiers in Immunology*, vol. 6, pp. 1–7, 2015.

[39] L. K. A. M. Leal, M. Nechio, E. R. Silveira et al., "Anti-inflammatory and smooth muscle relaxant activities of the hydroalcoholic extract and chemical constituents from Amburana cearensis A. C. Smith," *Phytotherapy research : PTR*, vol. 17, no. 4, pp. 335–340, 2003.

[40] Z. Balion, K. Ramanaukskienė, A. Jekabsone, and D. Majienė, "The role of mitochondria in brain cell protection from ischaemia by differently prepared propolis extracts," *Antioxidants*, vol. 9, no. 12, pp. 1–20, 2020.

[41] P. de Araújo Rodrigues, S. M. de Morais, J. F. Pereira et al., "Neuroprotective effects of proanthocyanidins of grape seed extracts against oxidative stress and apoptosis induced by 6-hydroxydopamine in PC12 cells," *Conjecturas*, vol. 21, no. 2, pp. 68–86, 2021.
[42] T. Ahmed, A. Zulfiqar, S. Arguelles et al., “Map kinase signaling as therapeutic target for neurodegeneration,” *Pharmacological Research*, vol. 160, 2020.

[43] C. J. Wei, Y. L. Li, Z. L. Zhu et al., “Inhibition of activator protein 1 attenuates neuroinflammation and brain injury after experimental intracerebral hemorrhage,” *CNS Neuroscience and Therapeutics*, vol. 25, no. 10, pp. 1182–1188, 2019.

[44] M. Rahimifard, F. Maqbool, S. Moeini-Nodeh et al., “Targeting the TLR4 signaling pathway by polyphenols: a novel therapeutic strategy for neuroinflammation,” *Ageing Research Reviews*, vol. 36, pp. 11–19, 2017.

[45] C. R. A. Batista, G. F. Gomes, E. Candelario-Jalil, B. L. Fiebich, and A. C. P. de Oliveira, “Lipopolysaccharide-induced neuroinflammation as a bridge to understand neurodegeneration,” *International Journal of Molecular Sciences*, vol. 20, no. 9, p. 2293, 2019.